Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2011-02-01 | Apeiron Biologics (Austria) Merck KGaA, , Merck Serono (Germany) | hu14.18-IL2 | pediatric neuroblastoma - melanoma | licensing |
Cancer - Oncology | Licensing agreement |
2011-01-31 | Newron (Italy) Merck Serono (Germany) | pruvanserin and sarizotan | CNS diseases | Licensing |
CNS diseases | Licensing agreement |
2011-01-28 | MDxHealth (Belgium) Pfizer (USA - NY) Newcastle University (UK) Cancer Research Technology Limited (CRT) UK | biomarker predicting response to PF-01367338, drug candidate for PARP inhibition | ovarian cancer breast cancer | R&D development |
Cancer - Oncology | R&D agreement |
2011-01-28 | ALK (Denmark)Torii Pharmaceutical Co (Japan) | house dust mite allergy immunotherapy products (Mitizak®, Alutard®) | asthma - allergic rhinitis | development |
Respiratory diseases - Inflammatory diseases - Allergic diseases | Development agreement |
2011-01-27 | Bayer HealthCare (Germany) Zydus Cadila (India) | joint-venture |
Gynecology - Diagnostic imaging - Cardiovascular diseases - Metabolic diseases - Cancer - Oncology | Collaboration agreement | ||
2011-01-26 | Swedish Orphan Biovitrum (Sweden) Fresenius Biotech (Germany) | Removab® (catumaxomab) | malignant ascites in patients with EpCAM (Epithelial Cell Adhesion Molecule) positive carcinomas where standard therapy is not available or no longer feasible. | Distribution |
Cancer - Oncology | Distribution agreement |
2011-01-25 | Cerep (France) Shire (UK-USA) | BioPrint® (pharmacology and ADME database) | Licensing |
Licensing agreement | ||
2011-01-25 | Oxford BioTherapeutics (UK) Sanofi-Aventis (France) | preclinical antibody program | Licensing |
Cancer - Oncology | Licensing agreement | |
2011-01-24 | MediGene (Germany) Meditrina Pharmaceuticals (Greece) | Veregen® ointment (made from the extract of green tea leaves - catechins) | External genital warts | commercialisation |
Gynecology - Infectious diseases | Distribution agreement |
2011-01-17 | Domain Therapeutics (France) Merck Serono (Germany) | metabotropic glutamatereceptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs | Parkinson’s disease and other neurodegenerative diseases | Development |
Neurodegenerative diseases - CNS diseases | Development agreement |
2011-01-17 | Polyplus-transfection (France)Roche Glycart (Switzerland) | polyethylenimine (PEI) for in vitro transfection applications for research purposes | Licensing |
Licensing agreement | ||
2011-01-17 | Faron Pharmaceuticals Ltd (Finland) Rentschler Biotechnologie GmbH (Germany) | Traumakine® (FP-1201- recombinant human interferon beta-1a (IFN-beta 1a) | prevention of vascular leakage in patients with acute lung injuries (ALI) and its more severe form acute respiratory distress syndrome (ARDS) | Manufacturing |
Respiratory diseases | Production agreement |
2011-01-13 | MediGene AG (Germany) Laboratoires Expanscience (France ) | Veregen® ointment (made from the extract of green tea leaves - catechins) | external genital warts | commercialisation |
Gynecology - Infectious diseases | Commercialisation agreement |
2011-01-13 | Ipsogen (France) Stanford University (USA) | LNK mutations | myeloid disorders | Licensing |
Cancer - Oncology | Licensing agreement |
2011-01-13 | Cancer Research UK (UK) AstraZeneca (UK) | combinations of new cancer drugs | cancer | R&D |
Cancer - Oncology | R&D agreement |
2011-01-12 | Sanofi-Aventis ( France) University of California, San Francisco - UCSF (USA) | pain - inflammation | R&D |
CNS diseases - Inflammatory diseases - Immunological diseases - Metabolic diseases | R&D agreement | |
2011-01-12 | Sanofi-Aventis ( France) University of California, San Francisco -UCSF (USA) | R&D |
Cancer - Oncology | R&D agreement | ||
2011-01-11 | Swedish Orphan Biovitrum (Sweden) BL&H Co Ltd (Better Life & Health) (South Korea) | Orfadin® (nitisinone) | tyrosinaemia type 1 (HT-1) | Distribution | Rare diseases | |
2011-01-11 | Swedish Orphan Biovitrum (Sweden) BL&H Co Ltd (Better Life & Health) (South Korea) | Kepivance® (palifermin). Swedish Orphan Biovitrum has acquired from Amgen the global rights for this modified version of human keratinocyte growth factor in September 2008. | mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support | Distribution | Cancer Oncology | |
2011-01-11 | Vivalis (France) Merial | EB66® cell line for the manufacturing of a veterinary vaccine | licensing | Veterinary medicine |